(Q37506092)

20 August 2017

1 reference

title

Systemic lupus erythematosus clinical trials-an interim analysis (English)

1 reference

systemic lupus erythematosus

20 August 2017

0 references

author name string

Maria Dall'Era

series ordinal

1

1 reference

PubMed ID

19491915

20 August 2017

David Wofsy

series ordinal

2

1 reference

PubMed ID

19491915

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Nature Reviews Rheumatology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

6

1 reference

20 August 2017

348-351

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2009.79

20 August 2017

0 references

cites work

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/19491915

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Sequential therapies for proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.79

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19491915

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2009.79

1 reference

20 August 2017

1 reference

PubMed ID

19491915